Leukoreduction and blood-borne vCJD transmission risk

Current Opinion in Hematology

Volumn 22, Issue 1, 2015, Pages 36-40

  Douet, Jean Yves ^a   Bujdoso, Raymond ^b   Andréoletti, Olivier ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Leukoreduction; Transfusion; Transmission prevention; Variant Creutzfeldt'Jakob disease

Indexed keywords

BIOASSAY; BLOOD; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; BOVINE SPONGIFORM ENCEPHALOPATHY; CELL VIABILITY; DISEASE TRANSMISSION; ERYTHROCYTE; HUMAN; INFECTION PREVENTION; INFECTION RISK; LEUKAPHERESIS; LEUKOCYTE; NONHUMAN; PLASMA; PRION; PRION DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THROMBOCYTE; UNITED KINGDOM; VARIANT CREUTZFELDT JAKOB DISEASE; ADVERSE EFFECTS; ANIMAL; BLOOD COMPONENT THERAPY; BOVINE; CREUTZFELDT-JAKOB SYNDROME; TRANSMISSION;

ANIMALS; BLOOD COMPONENT TRANSFUSION; CATTLE; CREUTZFELDT-JAKOB SYNDROME; GREAT BRITAIN; HUMANS; LEUKOCYTE REDUCTION PROCEDURES;

EID: 84916913822     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000101     Document Type: Review

References (26)

1. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 389:498-501.
2. Collinge J, Sidle KC, Meads J, et al. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383:685-690.
3. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997; 349:99-100.
4. Brown P, Rohwer RG, Dunstan BC, et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 1998; 38:810-816.
5. Brown P, Cervenakova L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalo-pathy, with an explanation of why blood components do not transmit Creutz-feldt-Jakob disease in humans. Transfusion 1999; 39:1169-1178.
6. Gregori L, Gurgel PV, Lathrop JT, et al. Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 2006; 368:2226-2230.
7. Peden A, McCardle L, Head MW, et al. Variant CJD infection in the spleen ofa neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010; 16:296-304.
8. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob diseaseby blood transfusion. Lancet 2004; 363:417-421.
9. Peden AH, Head MW, Ritchie DL, et al. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527-529.
10. Lefrere JJ, Hewitt P. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France. Transfusion 2009; 49:797-812.
11. Cervenakova L, YakovlevaO, McKenzie C, et al. Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 2003; 43:1687-1694.
12. Holada K, Vostal JG, Theisen PW, et al. Scrapie infectivity in hamster blood is not associated with platelets. J Virol 2002; 76:4649-4650.
13. Lacroux C, Vilette D, Fernandez-Borges N, et al. Prionemia and leukocyte-platelet-associated infectivity in sheep transmissible spongiform encephalo-pathy models. J Virol 2012; 86:2056-2066.
14. Andreoletti O, Litaise C, Simmons H, et al. Highly efficient prion transmission by blood transfusion. PLoS Pathog 2012; 8:e1002782.
15. Mathiason CK, Hayes-Klug J, Hays SA, et al. B cells and platelets harbor prion infectivity in the blood of deer infected with chronic wasting disease. J Virol 2010; 84:5097-5107.
16. Douet JY, Zafar S, Perret-Liaudet A, et al. Detection of infectivity in blood of persons with variant and sporadic Creutzfeldt-Jakob disease. Emerg Infect Dis 2014; 20:114-117.
17. Lacroux C, Comoy E, Moudjou M, et al. Preclinical detection of variant CJD and BSE prions in blood. PLoS Pathog 2014; 10:e1004202.
18. Turner ML, Ludlam CA. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products. Br J Haematol 2009; 144:14-23.
19. Ironside JW, Bishop MT, Connolly K, et al. Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 2006; 332:1186-1188.
20. Ironside JW, Hilton DA, Ghani A, et al. Retrospective study of prion-protein accumulation in tonsil and appendix tissues. Lancet 2000; 355:1693-1694.
21. Hunter N, Foster J, Chong A, et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83 (Pt 11):2897-2905.
22. Houston F, Foster JD, Chong A, et al. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356:999-1000.
23. McCutcheon S, Alejo Blanco AR, Houston EF, et al. All clinically-relevant blood components transmit prion disease following a single blood transfusion: a sheep model of vCJD. PLoS One 2011; 6:e23169.
24. Lacroux C, Bougard D, Litaise C, et al. Impact of leucocyte depletion and prion reduction filtersonTSE blood borne transmission. PLoS One 2012;7:e42019.
25. Gregori L, Yang H, Anderson S. Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood. Transfusion 2011; 51:2596-2602.
26. Gill ON, Spencer Y, Richard-Loendt A, et al. Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013; 347:f5675.